



**HELMHOLTZ
ZENTRUM FÜR
INFEKTIONSFORSCHUNG**

**This is a pre- or post-print of an article published in
Bergmann, R., Dinkla, K., Patric Nitsche-Schmitz, D.,
Graham, R.M.A., Lüttge, M., Sanderson-Smith, M.L.,
Nerlich, A., Rohde, M., Chhatwal, G.S.
Biological functions of GCS3, a novel plasminogen-binding
protein of *Streptococcus dysgalactiae* ssp. *equisimilis*
(2011) *International Journal of Medical Microbiology*, 301
(2), pp. 157-164.**

1 **Biological functions of GCS3, a novel plasminogen binding protein of**
2 ***Streptococcus dysgalactiae ssp. equisimilis***

3
4 René Bergmann⁺, Katrin Dinkla⁺, D. Patric Nitsche-Schmitz, Rikki M. A. Graham, Melanie
5 Lüttge, Martina L. Sanderson-Smith, Andreas Nerlich, Manfred Rohde, and Gursharan S.
6 Chhatwal*

7
8
9 Address:

10 Department of Medical Microbiology, Helmholtz Centre for Infection Research, 38124
11 Braunschweig, Germany

12
13
14 Key words: streptococcus, infection, plasminogen, M protein, pharyngeal cells, streptokinase
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 ⁺equal contribution
39
40

41 *To whom correspondence should be addressed at: Department of Medical Microbiology,
42 Helmholtz Centre for Infection Research, Inhoffenstraße 7, 38124 Braunschweig, Germany
43 Email: gsc@helmholtz-hzi.de
44 Telephone: +49-(0)531-6181-4400 Fax: +49-(0)531-6181-4499

45 **Abstract**

46
47 Increasing awareness of the relevance of *S. dysgalactiae* ssp. *equisimilis* as a human pathogen
48 motivates the analysis of its pathomechanisms. One of the mechanisms that increases
49 infectivity and dissemination of several streptococcal species is the recruitment and
50 subsequent activation of host plasminogen on the streptococcal surface. This study identified
51 GCS3 as a novel plasminogen binding M-protein of *S. dysgalactiae* ssp. *equisimilis* and
52 revealed a difference in the mode of binding as compared to the plasminogen binding protein
53 PAM of *Streptococcus pyogenes*. In contrast to PAM, GCS3 did not bind to the kringle 1-3
54 region of plasminogen. Despite this difference GCS3 exerts the same function of recruiting
55 plasminogen to the streptococcal surface, which can be activated by streptokinase and host
56 plasminogen activators to serve as a spreading factor. Moreover, we demonstrate a role of
57 GCS3 in plasminogen dependent streptococcal adherence to human pharyngeal cells (cell line
58 Detroit 562) that indicates an additional function of the protein as an adhesin in the oral
59 cavity.

60 **Introduction**

61 *Streptococcus pyogenes* is a dominant cause for pyogenic streptococcal infections in human.
62 However, a considerable part of these infections is caused by *Streptococcus dysgalactiae*
63 subsp. *equisimilis* (herein abbreviated *S. equisimilis*). Strains of this species carry Lancefield
64 group C or G polysaccharides that are also found in a number of other streptococcal species
65 that infect animals or humans (for reference see: Facklam, 2002; Reißmann et al., 2010). *S.*
66 *equisimilis* causes a similar spectrum of disease as *S. pyogenes* comprising suppurative throat
67 and skin infections and is isolated from life-threatening invasive infections in human with an
68 alarming frequency (Broyles et al., 2009; Cohen-Poradosu et al., 2004; Ekelund et al., 2005;
69 Nohlgard et al., 1992; Sylvetsky et al., 2002)

70 Although genetically distinct species (Facklam, 2002), *S. pyogenes* and *S. equisimilis* share
71 several virulence factors (Davies et al., 2007), including the surface anchored M proteins
72 (Bisno et al., 1987; Broyles et al., 2009; Pinho et al., 2006; Reißmann et al., 2010; Simpson et
73 al., 1987) of which more than 150 are known to date. M proteins are coded by the *emm* genes,
74 which are specific for either streptococcal species. They contribute to the resistance of
75 streptococci to phagocytosis as well as to host colonization (for reference see: Nitsche-
76 Schmitz et al., 2007a). Although other plasminogen binding factors exist on the surface of *S.*
77 *pyogenes* such as the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and α -enolase
78 (Bergmann et al., 2001; Bergmann et al., 2004; Pancholi and Fischetti, 1998; Pancholi and
79 Fischetti, 1993), M proteins have evolved that confer to certain strains the ability to bind
80 substantial quantities of plasminogen. One of the best studied plasminogen binding M
81 proteins is PAM (Berge and Sjöbring, 1993; Walker et al., 2005; Wistedt et al., 1998). The
82 plasminogen binding domain of PAM displays a high degree of variability at the amino acid
83 level, likely due to host selective immune pressure since antibodies against this region are
84 opsonic (Sanderson-Smith et al., 2006a). However, despite the high sequence variability
85 plasminogen binding is retained, indicating that it has an important function on the surface of

86 *S. pyogenes* (Sanderson-Smith et al., 2006a; Sanderson-Smith et al., 2006b). Indeed, the
87 ability of *S. pyogenes* to bind plasminogen has been linked to a higher propensity to cause
88 invasive disease, since isolates from invasive infections bound more plasminogen than those
89 from non-invasive disease (McKay et al., 2004). Moreover, human plasminogen transgenic
90 mice showed an increased susceptibility to *S. pyogenes* infection (McKay et al., 2004; Sun et
91 al., 2004).

92

93 Plasminogen is the 92 kDa pro-enzyme form of plasmin, a key component of the mammalian
94 fibrinolytic system. It circulates in the human plasma and extracellular fluids at a
95 concentration of approx. 2 μ M and is composed of an N-terminal pro-peptide followed by 5
96 kringle domains and a catalytic C-terminal serine protease domain (Parry et al., 2000).
97 Proteolytic cleavage of the N-terminal 8 kDa peptide transforms the original Glu-plasminogen
98 into the pre-activated form Lys-plasminogen. The kringle domains contain lysine-binding
99 sites that allow binding to fibrinogen and to plasminogen receptors. The pro-enzyme is
100 activated by the specific plasminogen activators urokinase (uPA) and tissue-type plasminogen
101 activator (tPA) of the host, which cleave between the fifth kringle domain and the catalytic
102 domain at the bond between Arg₅₆₀ and Val₅₆₁ to generate the two-chained plasmin, which is
103 held together by inter-chain disulfide bridges. This activated broad range serine protease is
104 crucial for blood clot dissolution and exerts additional functions in cell migration and tissue
105 remodeling (Lähteenmäki et al., 2001; Parry et al., 2000). The ability to bind plasminogen on
106 their outer surface is not unique for streptococci, but observed for several other bacterial
107 species. Recruitment of its proteolytic activity is considered as a way for bacteria to increase
108 their dissemination (Lähteenmäki et al., 2001). The importance of this mechanism is
109 underlined by the fact that some human pathogenic streptococcal species like *S. pyogenes* and
110 *S. equisimilis* express streptokinase, which is a potent and specific activator for human
111 plasminogen. Moreover, plasminogen is readily activated by human tPA or uPA when bound

112 to the *S. pyogenes* surface. Plasminogen binding M proteins have also been identified in *S.*
113 *equisimilis* strains, namely MLC36 and MLG72. These proteins like PAM of *S. pyogenes*
114 bind to a fragment of plasminogen that comprises the kringle domains 1 to 3 (Ben Nasr et al.,
115 1994). Although it has not been studied sufficiently, it is likely that plasminogen binding
116 plays a similar important role in infections with *S. equisimilis* as it does for the virulence of *S.*
117 *pyogenes*. We have recently discovered the plasminogen binding activity of the *S. equisimilis*
118 M protein GCS3 and provide evidence for its diverse roles during infection.

119 **Results**

120 **Absorption of plasminogen from human plasma by *S. dysgalactiae* ssp.** 121 ***equisimilis***

122 The ability of different *S. equisimilis* strains to bind plasminogen was determined by
123 incubating the bacteria with human plasma and eluting bound proteins under acidic condition.
124 The amount of plasminogen in the eluates was visualized by SDS-PAGE and immunoblot
125 analysis, using specific antibodies against human plasminogen. Strains C90 and C107 as
126 opposed to strain G35 bound clearly detectable amounts of a protein that had the mobility of a
127 100 kDa protein in SDS-PAGE (Fig. 1A). The immunoblot identified this protein as
128 plasminogen (Fig. 1B). In a binding experiment with ¹²⁵I-labeled human plasminogen (14 ng,
129 100,000 cpm), strain C90 and C107 bound 78% and 51% of the added plasminogen,
130 respectively, indicating that the strains have a similar affinity for this protein as the PAM
131 expressing GAS strain (A158) that bound 61% (Fig. 1C). Sequencing of the *emm* genes
132 revealed that strain C107 (*emm* type *stc36*) carries the plasminogen binding M protein
133 MLC36 (Ben Nasr et al., 1994). The *emm*-gene of strain C90 (*emm* type *stc839*) encodes for
134 the M-protein GCS3. Binding of plasminogen to this M protein had not been shown
135 previously.

136 **GCS3 is a plasminogen binding factor of C90**

137 To investigate the role of GCS3 in plasminogen binding, GST-fusion proteins of MLC36
138 (GST-MLC36) and GCS3 (GST-GCS3) were examined for plasminogen binding in a dot blot
139 that was probed with human ¹²⁵I-plasminogen (25 µg, 1.8×10⁸ cpm). Both GCS3 and MLC36
140 showed concentration-dependent binding of plasminogen. No binding was seen with the
141 control M proteins GST-M6.1, GST-M3.1, which excluded interaction with the GST-tag. The
142 hexa-histidine tagged protein His₆-GRAB served as an additional negative control (Fig. 2A).

143 Concentration-dependent interaction between tag free GCS3 and human plasminogen was
144 observed in surface plasmon resonance measurements. An apparent dissociation constant of
145 $K_D = 18$ nM (Fig. 2B) could be determined based on the Langmuir model of a 1:1 interaction.
146 Thus, GCS3 binds to plasminogen with a similar affinity as PAM ($K_D = 1$ nM) (Berge and
147 Sjöbring, 1993). To study the ability of GCS3 to recruit plasminogen to the streptococcal
148 surface, the protein was heterologously expressed on the surface of *S. gordonii* strain GP1221.
149 Measuring binding of 125 I-plasminogen (14 ng, 100,000 cpm) revealed a significantly
150 increased binding of plasminogen to the GCS3 expressing recombinant *S. gordonii* (SGO
151 GCS3). This presents further evidence that GCS3 is a streptococcal plasminogen receptor
152 (Fig. 2C).

153 **GCS3 binding site in human plasminogen**

154 The *S. pyogenes* protein PAM and *S. equisimilis* proteins MLC36 and MLG72 (Ben Nasr et
155 al., 1994; Wistedt et al., 1998) bind to the lysine-binding sites in a fragment of plasminogen
156 that consists of the kringle domains 1 to 3 (kringle 1-3). To test whether GCS3 utilizes the
157 same contact site for plasminogen binding the following competition experiments were
158 performed. Binding of full-length 125 I-plasminogen (14 ng, 100,000 cpm) or 125 I-kringle 1-3
159 (14 ng, 100,000 cpm), respectively to *S. equisimilis* strain C90 and to the PAM expressing *S.*
160 *pyogenes* strain A158 was measured. Furthermore, the inhibitory effect of unlabeled kringle
161 1-3 (20 μ g) was tested (Fig. 3A). Although full-length 125 I-plasminogen bound to both C90
162 and A158, the 3400fold molar surplus of unlabeled kringle 1-3 did only interfere with binding
163 to A158 indicating that GCS3 of strain C90 bound to a different contact site on the full length
164 protein. This was supported by the observation that binding of 125 I-kringle 1-3 to C90 (18%)
165 was low, as compared to A158 (42%)(Fig. 3A). Like binding of 125 I-plasminogen to A158,
166 interaction with C90 can be inhibited by ϵ -aminocaproic acid (EACA) in a concentration-
167 dependent manner (Fig. 3B). Increased binding of 125 I-plasminogen due to expression of

168 GCS3 on the surface of *S. gordonii* can also be abolished by addition of EACA in
169 concentrations above 1 μ M. In summary the experiment indicates that the lysine analogue
170 EACA inhibits the interaction between human plasminogen and GCS3.

171 **Plasminogen activation and biological activity on the surface of *S.***
172 ***dysgalactiae* ssp. *equisimilis***

173 Inhibition experiments with kringle 1-3 indicated that the mode of the plasminogen
174 interaction differs between PAM and GCS3. To investigate whether GCS3-bound
175 plasminogen, like PAM-bound plasminogen, remains prone to activation, its ability to cleave
176 the chromogenic substrate S-2251 was measured. Incubation of C90 or SGO GCS3 with
177 human plasma (Fig. 4) or purified human plasminogen (data not shown) in the presence of
178 streptokinase led to an increased cleavage of S-2251 as compared to the negative control SGO
179 WT (Fig. 4A). Similarly, addition of the host plasminogen activator uPA, activated the
180 plasminogen that was bound to the GCS3 bearing strains (Fig. 4B). Biological activity of the
181 activated plasmin(ogen) was examined by measuring the degradation of immobilized ¹²⁵I-
182 fibrinogen (Fig. 5A). In absence of streptokinase the plasminogen-coated strains SGO GCS3
183 and SGO WT did not cause considerable proteolysis. In contrast, during incubation with *S.*
184 *equisimilis* strain C90, degradation of fibrinogen was observed, probably due to the
185 production of streptokinase. Addition of streptokinase increased the fibrinogen degradation,
186 which was about twice as high with the GCS3 bearing strains as with the GCS3-negative
187 SGO WT. This indicated a contribution of the GCS3-bound plasmin(ogen) to fibrinogen
188 digestion. Immunoblot analysis of a fibrinogen solution that was incubated with plasminogen
189 pre-incubated strains C90 and SGO GCS3 in the presence of streptokinase revealed that
190 degradation occurs also in solution (Fig. 5B). Plasminogen and streptokinase dependent
191 degradation of fibrin by SGO GCS3 was visualized by scanning electron microscopy (Fig. 6).
192 The results demonstrate that GCS3-bound plasminogen can be activated by streptokinase or

193 the host plasminogen activator uPA. The activated plasmin(ogen) degrades fibrinogen and its
194 coagulated form, fibrin. Interestingly, at the same conditions that were sufficient for
195 degradation of fibrinogen (Fig. 5D), we could not detect a proteolytic activity of the activated
196 plasmin(ogen) against fibronectin (Fig. 5C), suggesting a certain specificity for the
197 coagulation factor.

198

199 **Adherence to host cells**

200 Previous work suggested a role of plasminogen that is bound to the surface of *S. pyogenes* by
201 enolase and GAPDH in the colonization of human pharyngeal cells. Plasminogen acted as a
202 bridging molecule between the streptococcal proteins and Detroit 562 cells which are known
203 to express human α -enolase on their surface and bind Lys-plasminogen, preferentially
204 (Pancholi *et al.*, 2003). In an infection assay *S. equisimilis* C90 showed an increased
205 adherence to Detroit 562 cells when pre-coated with Lys-plasminogen (Fig. 7A). In order to
206 study the role of GCS3-bound plasminogen in adherence to these pharyngeal host cells, they
207 were infected with SGO GCS3 and SGO WT both in the presence or absence of Lys-
208 plasminogen. In both cases SGO WT showed low binding to the host cells while SGO GCS3
209 showed higher numbers of adherent bacteria. The increase in adherence due to expression of
210 GCS3 was observed in absence of plasminogen, but was amplified 3-fold by the pre-
211 incubation of SGO GCS3 with Lys-plasminogen (Fig. 7B). This result indicates that
212 plasminogen bound by M protein GCS3 adds to the adhesion to Detroit 562 cells and thus
213 could promote colonization of pharyngeal cells. Plasminogen dependent increase in adhesion
214 of GSC3 expressing streptococci was not observed with HEp-2 cells (Fig. 7C), indicating that
215 is has a certain cell type specificity.

216 **Discussion**

217 A deciding influence of the interaction between human plasminogen and streptococcal M
218 proteins like PAM on the pathogenesis of *S. pyogenes* infections has been demonstrated
219 previously (Sanderson-Smith et al., 2008). Activation of M protein-bound plasminogen is
220 considered as important for dissemination and invasion of *S. pyogenes*, since plasmin has a
221 broad range protease activity and possibly aids in degrading host tissue. It is becoming
222 increasingly clear that the M proteins of *S. dysgalactiae* ssp. *equisimilis*, which are found in
223 the great majority of strains that infect humans (Broyles et al., 2009; Pinho et al., 2006;
224 Reißmann et al., 2010), exert similar functions as the M proteins of *S. pyogenes*. They
225 increase the bacteria's resistance to phagocytosis by binding fibrinogen (Johansson et al.,
226 2004; Nitsche-Schmitz et al., 2007b) and facilitate adhesion to the host tissue, i. e. by binding
227 collagen (Barroso et al., 2009; Nitsche et al., 2006). The presented as well as earlier work
228 (Ben Nasr et al., 1994) identified plasminogen binding M proteins of *S. equisimilis* GCS3,
229 MLC 36 and MLG72 that may contribute to the ability of this streptococcal species to cause
230 severe invasive infections in a similar way as *S. pyogenes* M proteins. Our experiments allow
231 a comparison. Surface plasmon resonance measurements (Fig. 2B) revealed the high affinity
232 of the interaction which is in the same order of magnitude as the interaction of plasminogen
233 with PAM. However, binding and inhibition experiments indicated that GCS3, unlike PAM,
234 MLC36 and MLG72 (Ben Nasr et al., 1994; Wistedt et al., 1998), does not bind to the
235 plasminogen fragment that consists of the kringle domains 1 to 3 (kringle 1-3) (Fig. 3),
236 indicating that their plasminogen binding mechanisms differ. Inhibition experiments with the
237 lysine analogue EACA have shown that lysine binding sites in kringle 1-3 are responsible for
238 the interaction with PAM, MLC36 and MLG72. In case of PAM the kringle 2 domain of
239 plasminogen was identified as the binding site (Wistedt et al., 1998). Although, GCS3 did not
240 bind to kringle 1-3 its interaction with plasminogen could be inhibited by EACA. This
241 suggests the lysine binding sites of kringle domain 4 or 5 (Ho-Tin-Noe et al., 2005; Thewes et

242 al., 1990; Tulinsky et al., 1988) as the binding motif. Despite this considerable difference in
243 the mode of binding, the function of the interaction appeared to be conserved. Like PAM,
244 GCS3 is not able to activate plasminogen and to generate proteolytic activity, but the bound
245 pro-enzyme can be activated by streptokinase and host plasminogen activators (Fig. 4). The
246 plasminogen/streptokinase complex and the generated plasmin endowed the bacteria with a
247 substantial proteolytic activity as determined in assays with fibrinogen in solution (Fig. 5A)
248 and immobilized on a solid phase (Fig. 5B). Electron microscopic examination demonstrated
249 the plasmin(ogen)-dependent degradation of fibrin (Fig. 6), which suggests that the
250 proteolytic activity may be useful for *S. equisimilis* to escape from entrapment by blood
251 coagulation.

252

253 Plasminogen is present not only in human blood plasma but also in human saliva (Moody,
254 1982) which may be exploited by streptococci. Earlier experiments suggest that *S. pyogenes*
255 may recruit plasminogen with the help of streptococcal enolase in order to enhance adhesion
256 to pharyngeal cells (Pancholi et al., 2003). Our cell culture experiments demonstrate that the
257 plasminogen binding M protein GCS3 immobilizes sufficient amounts of plasminogen on the
258 streptococcal surface and in a mode that increases the adhesion to Detroit 562 human
259 pharyngeal cells (Fig. 7).

260

261 Emergence of *S. equisimilis* as an important human pathogen is leading to increased interest
262 in its mechanisms of pathogenesis. Apparently, one of them is the exploitation of
263 plasmin(ogen) for cell adhesion and degradation of host tissue to increase infectivity and
264 bacterial spread. Interference with these processes may support the treatment of severe
265 infections with *S. pyogenes* and *S. equisimilis*, two important human pathogens.

266 **Experimental procedures**

267 **Bacterial strains**

268 *Streptococcus pyogenes* strain A158 and *S. equisimilis* strains C90 , C107, and G35 were
269 isolated from throat swabs. Strains belonged to the *emm*-types emm53.0, stC839, stC36.0 and
270 stC5344, respectively. Streptococci were routinely grown at 37°C without agitation in Todd-
271 Hewitt broth supplemented with 0.5 % yeast extract (THY) or tryptic soy broth. For
272 cultivation of the recombinant *S. gordonii* strain GP1221, erythromycin was added to a final
273 concentration of 3 µg/ml. The strain was kindly provided by Dr. Gianni Pozzi (University of
274 Siena, Italy). *E. coli* strain (HB101), which was used for over expression of recombinant
275 proteins, was grown at 37°C with agitation in Luria Bertani broth with appropriate antibiotic
276 (100 µg/ml ampicillin (Amp)).

277 **Plasma absorption assay**

278 Streptococci from 50 ml overnight cultures were washed with PBS and resuspended to a
279 concentration of 10^9 CFU/ml by adjusting to a transmission at 600 nm of 10%. 1×10^{10}
280 bacteria were pelleted and resuspended in 400 µl PBS with 100 µl human plasma and
281 incubated at 37°C for 1 h. After removal of unbound proteins by washing three times with 1
282 ml of PBS, bound proteins were eluted with 50 µl 100mM Glycin/HCl, pH = 2 at RT for 15
283 min. Solid material was removed by centrifugation (5 min, $10,000 \times g$), before 40 µl of the
284 supernatant was collected and neutralized with 4 µl 1.5 M Tris-HCl, pH = 8.5. This sample
285 was mixed with an equal volume of SDS-PAGE sample buffer (62.5 mM Tris-HCl, 2% (w/v)
286 SDS, 0.001% (w/v) bromophenolblue, 5% (v/v) β-mercaptoethanol, 10% (v/v) glycerol, pH =
287 6.8), and subjected to SDS-PAGE using a 12% gel as described by Laemmli (Laemmli,
288 1970). Following electrophoresis, proteins were visualized by staining with Coomassie stain
289 (0.1% (w/v) Coomassie brilliant blue, 40% (v/v) methanol, 10% (v/v) acetic acid). For

290 immuno blots, proteins were transferred to nitrocellulose by the method of Towbin (Towbin
291 *et al.*, 1979). Membranes were blocked with 5% (w/v) skim milk powder in TBST (20 mM
292 Tris, 154 mM NaCl, 0.5% (v/v) Tween-20), and probed with polyclonal goat anti-human
293 plasminogen antibodies (1:3000 in TBST). After washing 3 times with TBST, the membrane
294 was probed with a rabbit anti-goat HRP-conjugated secondary antibody (1:5000 in TBST).
295 After washing 3 times with TBST, peroxidase activity was detected by chemoluminescence
296 using 100 mM Tris HCl, 1.25 mM 3-aminophthalhydrazide, 225 μ M p-coumaric acid, 0.01%
297 H₂O₂ at a pH = 8.8 in water and chemoluminescence films (GE Healthcare).

298 **¹²⁵I-plasminogen binding assay**

299 Full-length plasminogen or kringle 1-3 region of plasminogen (Sigma-Aldrich, Germany)
300 were labeled with ¹²⁵I by the chloramine T method and their binding to whole bacteria was
301 measured as reported elsewhere (McKay *et al.*, 2004). Briefly, 14 ng of ¹²⁵I-plasminogen was
302 added to 2.5×10^8 bacteria suspended in 250 μ l PBST and incubated at room temperature for
303 45 min. For inhibition experiments 20 μ g of unlabeled kringle 1-3 fragment or ϵ -
304 aminocaproic acid (1 nM to 300 μ M) were added to the sample. The cells were washed in
305 PBST and harvested by centrifugation. Supernatant was removed by careful aspiration and
306 pellet-associated radioactivity was measured in an automated Wallac gamma counter (Perkin
307 Elmer, Jugesheim, Germany). Protein binding was expressed as the percentage of total input
308 radioactivity (100,000 cpm). All measurements were carried out in triplicates.

309 **Cloning and expression of recombinant proteins**

310 For the generation of GST-GCS3 or GST-MLC36 proteins, GCS3 *emm* gene and MLC36
311 *emm* gene fragments were amplified from the chromosomal DNA of the appropriate strains
312 via PCR using the following primers: gcs3Bfor: 5' CAG AAG TTA AGG GAT CCC ATC
313 CGC GA 3' (BamHI restriction site); mlc36Bfor: 5' GAC AGT AGG ATC CAA CGG AGA

314 AGT TA 3' (BamHI restriction site); and mlc36Srev: 5' CAC CTG TTG AGT CGA CCT
315 GTC TCT TAG TTT 3' (SalI restriction site) for the full length proteins. Standard cloning
316 techniques were used to generate constructs in the pGEX-6P-1 vector system (GE Healthcare,
317 Freiburg, Germany). Proteins were expressed in *E. coli* HB101 and purified under native
318 conditions following the manufacturer's protocol. For production of tag free GCS3 the protein
319 was eluted from the affinity matrix by treatment with PreScission protease (GE Healthcare,
320 Freiburg, Germany) following the manufacturer's protocol.

321 **Construction of *S. gordonii* expression strains**

322 GCS3 was heterologously expressed on the surface of *S. gordonii* GP1221 as described by
323 Talay *et al.* (Talay *et al.*, 2000). The GCS3 *emm* gene was amplified using the primers
324 sgoSrev GCT TCT GCG TCG ACG TTT TCT TGC TCT and gcs3Bfor which is described
325 above.

326 **Dot-blot assay**

327 Recombinant GST tagged proteins GCS3 and MLC36 were dot-blotted onto nitrocellulose (5,
328 1, and 0.5 µg) before blocking with 5% (w/v) skim milk in PBS for 1 h at RT. The membrane
329 was washed for 5 min in PBS, and probed with 25 µg ¹²⁵I-plasminogen for 20 min, then
330 washed 3 times for 20 min with PBST. Plasminogen that was bound to the blot was detected
331 by exposing an x-ray film (BioMax MS film, Kodak, Germany).

333 **Surface plasmon resonance measurements**

334 Protein interactions were studied by surface plasmon resonance measurements in a BIAcore
335 2000 system (BIAcore AB) as described earlier (Nitsche *et al.*, 2006). Human plasminogen
336 (Sigma-Aldrich) was dissolved in 10 mM sodium acetate, pH = 5.0 at a concentration of 40
337 µg/ml. Injection of 20 µl at a flow rate of 5 µl/min led to immobilization of 600 response

338 units (RU) of plasminogen. Residual reactive groups were inactivated by a 7 min injection of
339 1 M ethanolamine, 0.1 M NaHCO₃, 0.5 M NaCl, 5 mM EDTA, pH = 8.0. Surface
340 regeneration was achieved by injection of three 20 s pulses of the same ethanolamine
341 solution. Recombinant GCS3 as the analyte was diluted in running buffer (50 mM HEPES,
342 150 mM sodium chloride, pH = 7.4) at concentrations of 0.5 μM, 1.0 μM, 2.0 μM and 4.0
343 μM. The interaction was measured at a flow rate of 10 μl/min. The BIAevaluation 3.0
344 software was used for further analysis of the data. Shown curves represent the difference
345 between the signal of the plasminogen-coupled surface and of a deactivated control surface
346 devoid of protein. They were further corrected by subtraction of the curve that was obtained
347 after injection of buffer alone. Buffer injection led to responses less than 5 RU.

348 **Plasminogen activity assay**

349 Streptococci of 50 ml overnight cultures were washed and adjusted to 10% transmission. 1 ×
350 10¹⁰ heat killed bacteria (20 min, 90°C) were incubated with plasma or 100 μg/ml purified
351 plasminogen in 1 ml PBS for 30 min. After washing with PBS, the bacteria were incubated
352 with 200 units streptokinase in 1 ml PBS for 1 h at 37°C, or 100 ng uPA in 1 ml PBS for 2 h
353 at 37°C. Bacteria were washed three times with PBS and pelleted by centrifugation. The
354 pellets were resuspended in 1 ml of a solution that contained the chromogenic substrate S-
355 2251 (80 μM in PBS). After incubation at 37°C for 2 h absorption of the supernatant was
356 measured at a wavelength of 405 nm.

357 **Protein degradation experiments**

358 Degradation of soluble fibrinogen or fibronectin was determined after pre-incubation with
359 plasma as described above. The pre-treated bacteria were incubated with 4 μg fibrinogen or
360 fibronectin for the indicated times at 37°C with or without 25 units of streptokinase. Samples
361 were taken at different time points and boiled with an equal volume of SDS-PAGE buffer

362 before being subjected to SDS-PAGE and Immunoblot analysis. Detection in immunoblots
363 was carried out as described above using rabbit anti-human fibrinogen antibody or rabbit anti-
364 human fibronectin antibody to probe. Degradation of immobilized ¹²⁵I-fibrinogen was
365 assessed by coating a 96-well microtitre plate with 2.5 µg/ml ¹²⁵I-fibrinogen overnight. 250 µl
366 of streptococci that had been pre-incubated with 50 µg plasminogen for 30 min at 37°C,
367 washed and resuspended in 1 ml PBS with or without 200 units streptokinase were added to
368 the wells and incubated for the indicated times. At each time point, 25 µl of supernatant of the
369 liquid phase were taken from the wells and radioactivity was measured as described above.

370 **Degradation of fibrin**

371 Fibrin was fibrillized on cover-slips by incubating 1 mg plasminogen depleted human
372 fibrinogen (Calbiochem, Darmstadt, Germany) with 25 U thrombin (from bovine plasma, MP
373 Biomedicals, Ohio, USA) for 12 h at 37°C in 100 µl PBS. SGO GCS3 pretreated with
374 plasminogen and streptokinase as described above, were applied with a dose of 1 x 10⁹ in 100
375 µl PBS containing 10 mM EDTA to the fibrin fibers for 2 h at 37 °C. Fibrin and its
376 degradation by SGO GCS3 was visualized by field emission scanning electron microscopy as
377 described earlier (Bergmann et al., 2005).

378 **Adherence/Invasion assays**

379 The human pharyngeal cell line Detroit 562 (ATCC CLL138) and HEp-2 cells (ATCC CCL-
380 23) was used for adherence and invasion assays with *S. equisimilis* C90 and *S. gordonii* SGO
381 GCS3 and SGO WT. Detroit 562 cells were grown in tissue culture plates containing RPMI
382 1640 medium (Gibco) supplemented with 10% fetal calf serum, L-glutamine (2 mM) and 1%
383 Na-pyruvate. HEp-2 cells were grown in tissue culture plates containing DMEM medium
384 (Gibco) supplemented with 10% fetal calf serum and L-glutamine (2 mM). Streptococcal
385 adhesion to eukaryotic cells was performed essentially as described elsewhere (Talay *et al.*,

386 2000). For adherence and invasion assay, bacteria were pre-coated with Lys-plasminogen
387 (final 0.74 $\mu\text{g}/\mu\text{l}$; Sigma-Aldrich, Germany) for 60 min at RT. Washed bacteria were
388 incubated with the cells in the presence of 3.2 units/ml of the trypsin inhibitor aprotinin
389 (Sigma-Aldrich, Germany) to inhibit the protease function of the bound plasmin(ogen).

390

391 **Acknowledgements**

392 This work was supported in part by the European Commission (INCO-CT-2006-032390-
393 ASSIST). MLS thanks Alexander von Humboldt Foundation, Bonn, Germany for the award
394 of a postdoctoral fellowship. We thank Marcus Fulde for critically reading the manuscript.
395

- 397 Barroso, V., Rohde, M., Davies, M. R., Gillen, C. M., Nitsche-Schmitz, D. P., Dinkla, K.,
398 Chhatwal, G. S., 2009. Identification of active variants of PARF in human pathogenic
399 group C and group G streptococci leads to an amended description of its consensus
400 motif. *Int J Med Microbiol.*
- 401 Ben Nasr, A., Wistedt, A., Ringdahl, U., Sjöbring, U., 1994. Streptokinase activates
402 plasminogen bound to human group C and G streptococci through M-like proteins.
403 *Eur J Biochem.* 222(2), 267-276
- 404 Berge, A., Sjöbring, U., 1993. PAM, a novel plasminogen-binding protein from *Streptococcus*
405 *pyogenes*. *J Biol Chem.* 268(34), 25417-25424
- 406 Bergmann, S., Rohde, M., Chhatwal, G. S., Hammerschmidt, S., 2001. alpha-Enolase of
407 *Streptococcus pneumoniae* is a plasmin(ogen)-binding protein displayed on the
408 bacterial cell surface. *Mol Microbiol.* 40(6), 1273-1287
- 409 Bergmann, S., Rohde, M., Hammerschmidt, S., 2004. Glyceraldehyde-3-phosphate
410 dehydrogenase of *Streptococcus pneumoniae* is a surface-displayed plasminogen-
411 binding protein. *Infect Immun.* 72(4), 2416-2419
- 412 Bergmann, S., Rohde, M., Preissner, K. T., Hammerschmidt, S., 2005. The nine residue
413 plasminogen-binding motif of the pneumococcal enolase is the major cofactor of
414 plasmin-mediated degradation of extracellular matrix, dissolution of fibrin and
415 transmigration. *Thromb Haemost.* 94(2), 304-311
- 416 Bisno, A. L., Craven, D. E., McCabe, W. R., 1987. M proteins of group G streptococci
417 isolated from bacteremic human infections. *Infect Immun.* 55(3), 753-757
- 418 Broyles, L. N., Van Beneden, C., Beall, B., Facklam, R., Shewmaker, P. L., Malpiedi, P.,
419 Daily, P., Reingold, A., Farley, M. M., 2009. Population-Based Study of Invasive
420 Disease Due to beta-Hemolytic Streptococci of Groups Other Than A and B. *Clin*
421 *Infect Dis.* 48(6), 706-712
- 422 Cohen-Poradosu, R., Jaffe, J., Lavi, D., Grisariu-Greenzaid, S., Nir-Paz, R., Valinsky, L.,
423 Dan-Goor, M., Block, C., Beall, B., Moses, A. E., 2004. Group G streptococcal
424 bacteremia in Jerusalem. *Emerg Infect Dis.* 10(8), 1455-1460
- 425 Davies, M. R., McMillan, D. J., Beiko, R. G., Barroso, V., Geffers, R., Sriprakash, K. S.,
426 Chhatwal, G. S., 2007. Virulence profiling of *Streptococcus dysgalactiae* subspecies
427 *equisimilis* isolated from infected humans reveals 2 distinct genetic lineages that do
428 not segregate with their phenotypes or propensity to cause diseases. *Clin Infect Dis.*
429 44(11), 1442-1454
- 430 Ekelund, K., Skinhoj, P., Madsen, J., Konradsen, H. B., 2005. Invasive group A, B, C and G
431 streptococcal infections in Denmark 1999-2002: epidemiological and clinical aspects.
432 *Clin Microbiol Infect.* 11(7), 569-576
- 433 Facklam, R., 2002. What happened to the streptococci: overview of taxonomic and
434 nomenclature changes. *Clin Microbiol Rev.* 15(4), 613-630
- 435 Ho-Tin-Noe, B., Rojas, G., Vranckx, R., Lijnen, H. R., Angles-Cano, E., 2005. Functional
436 hierarchy of plasminogen kringle 1 and 4 in fibrinolysis and plasmin-induced cell
437 detachment and apoptosis. *Febs J.* 272(13), 3387-3400
- 438 Johansson, H. M., Mörgelin, M., Frick, I. M., 2004. Protein FOG--a streptococcal inhibitor of
439 neutrophil function. *Microbiology.* 150(Pt 12), 4211-4221
- 440 Lähteenmäki, K., Kuusela, P., Korhonen, T. K., 2001. Bacterial plasminogen activators and
441 receptors. *FEMS Microbiol Rev.* 25(5), 531-552
- 442 McKay, F. C., McArthur, J. D., Sanderson-Smith, M. L., Gardam, S., Currie, B. J.,
443 Sriprakash, K. S., Fagan, P. K., Towers, R. J., Batzloff, M. R., Chhatwal, G. S.,
444 Ranson, M., Walker, M. J., 2004. Plasminogen binding by group A streptococcal

445 isolates from a region of hyperendemicity for streptococcal skin infection and a high
 446 incidence of invasive infection. *Infect Immun.* 72(1), 364-370
 447 Moody, G. H., 1982. Plasminogen in human saliva. *Int J Oral Surg.* 11(2), 110-114
 448 Nitsche-Schmitz, D. P., Johansson, H. M., Sastalla, I., Reissmann, S., Frick, I. M., Chhatwal,
 449 G. S., 2007b. Group G streptococcal IgG binding molecules FOG and protein G have
 450 different impacts on opsonization by C1q. *J Biol Chem.* 282(24), 17530-17536
 451 Nitsche-Schmitz, D. P., Rohde, M., Chhatwal, G. S., 2007a. Invasion mechanisms of Gram-
 452 positive pathogenic cocci. *Thromb Haemost.* 98(3), 488-496
 453 Nitsche, D. P., Johansson, H. M., Frick, I. M., Mörgelin, M., 2006. Streptococcal protein
 454 FOG, a novel matrix adhesin interacting with collagen I in vivo. *J Biol Chem.* 281(3),
 455 1670-1679
 456 Nohlgard, C., Björklind, A., Hammar, H., 1992. Group G streptococcal infections on a
 457 dermatological ward. *Acta Derm Venereol.* 72(2), 128-130
 458 Pancholi, V., Fischetti, V. A., 1998. alpha-enolase, a novel strong plasmin(ogen) binding
 459 protein on the surface of pathogenic streptococci. *J Biol Chem.* 273(23), 14503-14515
 460 Pancholi, V., Fischetti, V. A., 1993. Glyceraldehyde-3-phosphate dehydrogenase on the
 461 surface of group A streptococci is also an ADP-ribosylating enzyme. *Proc Natl Acad*
 462 *Sci U S A.* 90(17), 8154-8158
 463 Pancholi, V., Fontan, P., Jin, H., 2003. Plasminogen-mediated group A streptococcal
 464 adherence to and pericellular invasion of human pharyngeal cells. *Microb Pathog.*
 465 35(6), 293-303
 466 Parry, M. A., Zhang, X. C., Bode, I., 2000. Molecular mechanisms of plasminogen activation:
 467 bacterial cofactors provide clues. *Trends Biochem Sci.* 25(2), 53-59
 468 Pinho, M. D., Melo-Cristino, J., Ramirez, M., 2006. Clonal relationships between invasive
 469 and noninvasive Lancefield group C and G streptococci and emm-specific differences
 470 in invasiveness. *J Clin Microbiol.* 44(3), 841-846
 471 Reißmann, S., Friedrichs, C., Rajkumari, R., Itzek, A., Fulde, M., Rodloff, A. C.,
 472 Brahmadathan, K. N., Chhatwal, G. S., Nitsche-Schmitz, D. P., 2010. Contribution of
 473 *Streptococcus anginosus* to Group C and G Streptococcal Infections, South India.
 474 *Emerg Infect Dis.* 16(4), in press
 475 Sanderson-Smith, M., Batzloff, M., Sriprakash, K. S., Dowton, M., Ranson, M., Walker, M.
 476 J., 2006a. Divergence in the plasminogen-binding group a streptococcal M protein
 477 family: functional conservation of binding site and potential role for immune selection
 478 of variants. *J Biol Chem.* 281(6), 3217-3226
 479 Sanderson-Smith, M. L., Dinkla, K., Cole, J. N., Cork, A. J., Maamary, P. G., McArthur, J.
 480 D., Chhatwal, G. S., Walker, M. J., 2008. M protein-mediated plasminogen binding is
 481 essential for the virulence of an invasive *Streptococcus pyogenes* isolate. *Faseb J.*
 482 22(8), 2715-2722
 483 Sanderson-Smith, M. L., Walker, M. J., Ranson, M., 2006b. The maintenance of high affinity
 484 plasminogen binding by group A streptococcal plasminogen-binding M-like protein is
 485 mediated by arginine and histidine residues within the a1 and a2 repeat domains. *J*
 486 *Biol Chem.* 281(36), 25965-25971
 487 Simpson, W. J., Robbins, J. C., Cleary, P. P., 1987. Evidence for group A-related M protein
 488 genes in human but not animal-associated group G streptococcal pathogens. *Microb*
 489 *Pathog.* 3(5), 339-350
 490 Sun, H., Ringdahl, U., Homeister, J. W., Fay, W. P., Engleberg, N. C., Yang, A. Y., Rozek, L.
 491 S., Wang, X., Sjobring, U., Ginsburg, D., 2004. Plasminogen is a critical host
 492 pathogenicity factor for group A streptococcal infection. *Science.* 305(5688), 1283-
 493 1286

- 494 Sylvetsky, N., Raveh, D., Schlesinger, Y., Rudensky, B., Yinnon, A. M., 2002. Bacteremia
495 due to beta-hemolytic Streptococcus group G: increasing incidence and clinical
496 characteristics of patients. *Am J Med.* 112(8), 622-626
- 497 Thewes, T., Constantine, K., Byeon, I. J., Llinas, M., 1990. Ligand interactions with the
498 kringle 5 domain of plasminogen. A study by ¹H NMR spectroscopy. *J Biol Chem.*
499 265(7), 3906-3915
- 500 Tulinsky, A., Park, C. H., Mao, B., Llinas, M., 1988. Lysine/fibrin binding sites of kringles
501 modeled after the structure of kringle 1 of prothrombin. *Proteins.* 3(2), 85-96
- 502 Walker, M. J., McArthur, J. D., McKay, F., Ranson, M., 2005. Is plasminogen deployed as a
503 Streptococcus pyogenes virulence factor? *Trends Microbiol.* 13(7), 308-313
- 504 Wistedt, A. C., Kotarsky, H., Marti, D., Ringdahl, U., Castellino, F. J., Schaller, J., Sjobring,
505 U., 1998. Kringle 2 mediates high affinity binding of plasminogen to an internal
506 sequence in streptococcal surface protein PAM. *J Biol Chem.* 273(38), 24420-24424

507 **Figure Legends**

508 **Figure 1: Binding of human plasminogen to streptococci.** Streptococci were incubated
509 with human plasma in PBS (+) or PBS alone (-) for 1 h at 37°C. Unbound proteins were
510 removed. Bound proteins were eluted and analyzed by SDS-PAGE (12% gel) (A) and
511 immunoblot probing with polyclonal anti-human plasminogen antibody (B). Potential
512 plasminogen bands in A are indicated by arrow heads. Molecular mass standards in kDa are
513 indicated at the left. (C) Bacteria were incubated with human ¹²⁵I-plasminogen for 1 h at RT.
514 Bound plasminogen was quantified by measuring the radioactivity associated with the
515 bacteria. Results are expressed as percentage of the total radioactivity added (100,000 cpm).
516 *S. pyogenes* A158 is a PAM positive strain that served as a positive control.

517

518 **Figure 2: Interaction between human plasminogen and M protein GCS3 of *S.***
519 ***dysgalactiae* ssp. *equisimilis*.** (A) The recombinant GST-fusion proteins GST-GCS3, GST-
520 MLC36, GST-M6.1, GST-M3.1 and His₆-GRAB were dot-blotted onto a nitrocellulose
521 membrane in the indicated quantities and probed with ¹²⁵I-plasminogen. Surface plasmon
522 resonance sensograms of the interaction between tag free M-protein GCS3 in the liquid phase
523 and immobilized plasminogen are depicted in B. Measurements were carried out at the
524 indicated concentrations of GCS3. Injection started at t = 0 s and ended at t = 120 s. Based on
525 the Langmuir model of a 1:1 interaction, an apparent dissociation constant of K_d = 18 nM was
526 determined. (C) The *S. equisimilis* strain that bears GCS3 (C90), wild type *S. gordonii*
527 GP1221 (SGO WT), and the recombinant variant that expresses GCS3 M-protein (SGO
528 GCS3) were incubated with ¹²⁵I-plasminogen, quantities of bound protein were expressed as
529 the percentage of total radioactivity input (100,000 cpm).

530

531 **Figure 3: Role of plasminogen kringle domains 1 to 3 in M protein interaction.** (A)
532 Binding of ¹²⁵I-plasminogen to *S. pyogenes* strain A158 (A158) and *S. equisimilis* strain C90

533 (C90) was measured in absence (*black bars*) and presence (*grey bars*) of the unlabeled
534 plasminogen fragment that comprises kringle domains 1-3 (kringle 1-3). In addition, binding
535 of ¹²⁵I-kringle 1-3 was determined (*white bars*). (B) binding of ¹²⁵I-plasminogen to A158
536 (triangles), C90 (squares), *S. gordonii* strains SGO wt and SGO GCS3 was tested in presence
537 of EACA at different concentrations. The results in A and B are displayed as the percentage
538 of the total radioactivity added (100,000 cpm). Data show mean values ± SD of one
539 representative experiment performed in triplicate. Tukey's post-hoc test was used for
540 statistical analysis. P-values are given in A.

541

542 **Figure 4: Activation of plasminogen bound to the streptococcal surface by GCS3.** *S.*
543 *equisimilis* strain C90 and the *S. gordonii* strains SGO GCS3 and SGO WT were pre-
544 incubated with human plasma. Unbound proteins were removed before proteolytic activity
545 against the chromogenic substrate S-2251 was measured in the presence (*black bars*) or
546 absence (*white bars*) of streptokinase (A) or uPA (B). Substrate conversion is expressed as
547 absorbance at 405 nm.

548

549 **Figure 5: Degradation of fibrinogen by GCS3-bound plasminogen.** Following pre-
550 incubation with plasma (A) or plasminogen (B) and removal of unbound protein, *S.*
551 *equisimilis* strain C90 and the *S. gordonii* strains SGO GCS3 and SGO WT were incubated
552 with fibrinogen for the indicated times at 37°C. (A) Degradation of ¹²⁵I-fibrinogen
553 immobilized in a microtitre plate was measured for *S. equisimilis* strain C90 (*squares*) and the
554 *S. gordonii* strains SGO GCS3 (*triangles*) and SGO WT (*circles*) in presence (*filled symbols*)
555 and absence (*open symbols*) of streptokinase. Degradation was quantified over time as
556 radioactivity in cpm released into the liquid phase. (B) Samples in which bacteria were co-
557 incubated with fibrinogen in solution were analyzed by immunoblot (12% gel) with
558 antibodies specific for fibrinogen. Negative controls (lanes 2 and 8) were incubated without

559 streptokinase for 4 h. For the experiment depicted in C and D strain C90 was preincubated
560 with human plasminogen where indicated with +. Using bacteria from the same culture their
561 proteolytic effect on fibronectin (C) and fibrinogen (D) in presence + or absence - of
562 streptokinase was investigated. The samples were analyzed by immunoblot (10% gel) with
563 antibodies specific for fibronectin (C) or fibrinogen (D), respectively. Molecular mass
564 standards in kDa are indicated at the left in B, C and D.

565

566 **Figure 6: Electron microscopy of fibrin bundle degradation.** *S. gordonii* strain SGO GCS3
567 was incubated with fibrillated human fibrin in the presence of plasminogen. After addition of
568 streptokinase (A-C) degradation of the fibers was observed discernible by massive formation
569 of thin fibrillar structures. The control sample without streptokinase lacks these signs of fibrin
570 degradation (D). Bars represent 5 μm in A and 1 μm in B-D.

571

572 **Figure 7: Adherence to Detroit 562 cells.** Monolayers of Detroit 562 cells (A and B) or
573 HEp-2 cells (C) were infected with *S. equisimilis* strain C90 (A), the *S. gordonii* strains SGO
574 GCS3 (B and C) and SGO WT (B) in the presence (*black bars*) or absence (*white bars*) of lys-
575 plasminogen. The number of adherent bacteria was determined after 2 h. Adherence is
576 expressed as percentage of the initial inoculum. A value above 100% is due to bacterial
577 growth during incubation. Data show mean values \pm SD of one representative experiment
578 performed in triplicate.